Page 13 - Pharma Sector

Lupin to boost complex generics in US, EU; eyes chronic growth in India

Lupin plans to expand complex generics in developed markets and grow its chronic drug portfolio in India, with over 200 product launches and M&A on the radar

Trump's plans to cut drug prices in US may impact Indian pharma landscape

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

Lupin Q4 results: Net profit zooms by 112% to ₹782 cr, revenue up 14%

The company's revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, from ₹4,961 crore in Q4FY24

Cipla Q4FY25 results: Net profit zooms 30% to ₹1,221 cr, revenue up 9%

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent

Margin pressures, growth triggers to weigh on Dr Reddy's Laboratories

The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term

Dr Reddy's Q4 results preview: Analysts eye 18% jump in PAT; check details

Dr Reddy's Labs Q4 results 2025 date: Dr Reddy's Laboratories is scheduled to announce its fourth quarter (Q4FY25) results on Friday, May 9, 2025

Insulin's century-old legacy still stands tall amid new diabetes drugs

Despite the rise of GLP-1s and oral therapies, insulin remains vital for millions, particularly those with type 1 diabetes and other insulin-dependent conditions

Trump targets foreign drugs: Tariffs in 2 weeks, begins US mfg push

US President Trump has signed executive orders to speed up drug approvals and pharma infrastructure construction in the US

Akums secures patent for dual-action nausea drug for pregnant women

Akums receives DCGI approval for a dual-release Doxylamine-Pyridoxine tablet designed to relieve nausea and vomiting in pregnancy with reduced dosing frequency

Triton Logistics aims to grow turnover to ₹500 crore in 2 to 3 years

Triton Logistics & Maritime is aiming to increase its turnover to Rs 500 crore from the current Rs 150 crore in the next two to three years, its CEO Jitendra Srivastava said on Friday. "Triton is still in a very early stage. Right now, we're touching around Rs 150 crore in turnover. The aim is to scale this up to Rs 500 crore in the next two to three years," the CEO said. The company which specialises in freight forwarding, logistics, and global supply chain management with end-to-end solutions plans to scale up its turnover by investing into a lot of services and solutions, he said. "Our business plan is focused around two main pillars - geography and industry. On one hand, we are looking at which geographies we want to expand into, on the other hand, we are identifying industries where we can deliver tailored solutions," he explained. Apart from that, the company is putting a lot of effort into digitalisation and that's a major area where Triton Logistics & Maritime is ...

Blue Jet Healthcare jumps 6% as MOFSL initiates coverage, 26% upside seen

Blue Jet Healthcare's stock was quoting at ₹715, up 4.32 per cent on the National Stock Exchange

Mutual Funds increased stake in 14 pharma stocks in Q4FY25; do you own any?

Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.

These 3 pharma stocks have surged over 50% in April; check full list here

A total of 11 pharma and healthcare-related stocks have rallied more than 20% thus far in April on hopes of a likely softer tariff-related stance by the US President Donald Trump.

Booster dose: India inches closer to regulatory framework for OTC drugs

DTAB has accepted sub-panel recommendation on OTC drugs list

Is your heartburn pill safe? Panel recommends banning ranitidine in India

An expert panel has recommended suspending ranitidine after tests found cancer-linked NDMA levels in half the samples, bringing India closer to a nationwide ban

Divi's Labs jumps 4% after signing supply agreement with global pharma firm

Divi's Labs stock was quoting at ₹5,855.50, up 3.81 per cent from Thursday, April 17 close of ₹5,640

Hospital valuations keep steady pulse, ensuring growth never skips a beat

Administering the right dose for asset-light expansion and steady margins

Zydus Medtech signs deal with Brazil's Braile Biomedica for TAVI technology

To commercialise transcatheter aortic valve system in India, Europe and other select markets

Indian pharma companies eye larger share of US cancer generics market

Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures in the generics space in the US

Results preview: Domestic dose likely to ease US drag for pharma firms

Nuvama Institutional Equities said therapies like antidiabetic, anti-infective and respiratory had underperformed in the Indian pharma market